CN1824075B - 一种治疗偏头痛的药物组合物及其制备方法 - Google Patents
一种治疗偏头痛的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1824075B CN1824075B CN2005100622424A CN200510062242A CN1824075B CN 1824075 B CN1824075 B CN 1824075B CN 2005100622424 A CN2005100622424 A CN 2005100622424A CN 200510062242 A CN200510062242 A CN 200510062242A CN 1824075 B CN1824075 B CN 1824075B
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- capsule
- pharmaceutical composition
- radix angelicae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010019233 Headaches Diseases 0.000 title abstract description 21
- 239000000203 mixture Substances 0.000 title description 8
- 239000002775 capsule Substances 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 17
- 239000000341 volatile oil Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000003921 oil Substances 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 206010013786 Dry skin Diseases 0.000 claims description 5
- 241000545442 Radix Species 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 229950005162 benexate Drugs 0.000 claims description 5
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000004570 mortar (masonry) Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000009636 Huang Qi Substances 0.000 claims 1
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 1
- 239000000890 drug combination Substances 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 229940070765 laurate Drugs 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 58
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 34
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 29
- 231100000869 headache Toxicity 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 230000036407 pain Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 208000019695 Migraine disease Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000010171 animal model Methods 0.000 description 10
- 206010027599 migraine Diseases 0.000 description 10
- 238000003304 gavage Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229960002275 pentobarbital sodium Drugs 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000000919 ceramic Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000004622 sleep time Effects 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 4
- 230000002567 autonomic effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 206010003084 Areflexia Diseases 0.000 description 2
- 244000257039 Duranta repens Species 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035620 dolor Effects 0.000 description 2
- 230000000517 effect on sleep Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000028527 righting reflex Effects 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100622424A CN1824075B (zh) | 2005-12-27 | 2005-12-27 | 一种治疗偏头痛的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100622424A CN1824075B (zh) | 2005-12-27 | 2005-12-27 | 一种治疗偏头痛的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1824075A CN1824075A (zh) | 2006-08-30 |
CN1824075B true CN1824075B (zh) | 2010-12-22 |
Family
ID=36935016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005100622424A Expired - Fee Related CN1824075B (zh) | 2005-12-27 | 2005-12-27 | 一种治疗偏头痛的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1824075B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1925214A1 (en) * | 2006-11-24 | 2008-05-28 | DSMIP Assets B.V. | Dietary and pharmaceutical compositions containing carnosol and/or rosmanol and their uses |
CN105853765A (zh) * | 2016-05-06 | 2016-08-17 | 威海市中心医院 | 一种治疗偏头痛的中药复方制剂及其制备方法 |
-
2005
- 2005-12-27 CN CN2005100622424A patent/CN1824075B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1824075A (zh) | 2006-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101444611A (zh) | 治疗腰腿痛、腰椎间盘突出症的中药组合物及其制备方法 | |
CN102580000B (zh) | 一种治疗癌性疼痛药物及其制备方法 | |
CN1824075B (zh) | 一种治疗偏头痛的药物组合物及其制备方法 | |
CN101129633B (zh) | 一种治疗神经衰弱的药物及其制备方法 | |
CN103341092A (zh) | 一种治疗萎缩性阴道炎的散剂制备方法 | |
CN103356932B (zh) | 一种治疗外阴鳞状上皮细胞增生的药物组合物 | |
CN103301353A (zh) | 一种治疗萎缩性阴道炎的药物组合物 | |
CN106798782A (zh) | 一种治疗湿疹的中药组合物及其制备方法与用途 | |
CN102225155B (zh) | 一种治疗肺纤维化的药物组合物 | |
CN100471488C (zh) | 一种温阳益气、养心安神的中药组合物及其制备方法 | |
CN100411672C (zh) | 一种治疗银屑病的药物组合物 | |
CN104055925A (zh) | 一种治疗糖尿病周围神经病变的中药组合物 | |
CN105194352B (zh) | 一种改善学习记忆的中药组合物及其制备方法 | |
CN108379367A (zh) | 毒品戒断的纯中药药物及其制备方法 | |
CN108514627A (zh) | 一种治疗慢性荨麻疹的中药组合物 | |
CN112043757B (zh) | 一种养生咖啡及中药组合物 | |
CN103083597B (zh) | 一种治疗慢性支气管炎的药物组合物及其制法 | |
CN103157040A (zh) | 一种治疗多发性骨软骨瘤的药物组合物 | |
CN105832885A (zh) | 治疗失眠的中药组合物 | |
CN103191340A (zh) | 一种骨软骨瘤的护理药物 | |
CN113546131A (zh) | 一种用于治疗哮喘病的巴布贴 | |
CN104435785B (zh) | 一种用于治疗睡眠障碍的中药组合物、制备方法及用途 | |
CN103006957A (zh) | 一种预防和治疗骨质疏松的药物组合物及其制备方法 | |
CN113041333A (zh) | 一种治疗精神分裂症的中药药物及其制备方法 | |
CN103191336B (zh) | 一种治疗食道失弛缓症药物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG LVSHIJIE BIOLOGICAL ENGINEERING CO., LTD. Free format text: FORMER OWNER: YANG XIONGZHI Effective date: 20110808 Free format text: FORMER OWNER: YANG YIKAI |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 315100 NINGBO, ZHEJIANG PROVINCE TO: 313300 HUZHOU, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110808 Address after: 313300 health medical industry park, Anji Economic Development Zone, Zhejiang, Huzhou Patentee after: Zhejiang Green World Bio-Tech Engineering Co., Ltd. Address before: 315100 Zhejiang city of Ningbo province Yinzhou District County Road No. 888 East Zhejiang Pharmaceutical College Co-patentee before: Yang Yijie Patentee before: Yang Xiongzhi |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101222 Termination date: 20141227 |
|
EXPY | Termination of patent right or utility model |